NASDAQ:TLGT Teligent (TLGT) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free TLGT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.0552-Week Range N/AVolume6,460 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Teligent alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Teligent Stock (NASDAQ:TLGT)Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) TLGT Stock News HeadlinesApril 23, 2023 | wsj.comIDT Corp. Cl BJuly 18, 2022 | finance.yahoo.comLidocaine Market Size is projected to reach USD 3.05 Billion by 2029, growing at a CAGR of 8.45%: Straits Research - Yahoo FinanceMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJune 21, 2022 | law360.comRevlon Case Opens, And LATAM Lands Its Ch. 11 Plan - Law360June 17, 2022 | law360.comTeligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt - Law360May 3, 2022 | finance.yahoo.comTopical Drugs Market Size to Grow by USD 70.95 billion from 2021 to 2026 | Driven by Increase in the Prevalence of Skin Diseases | Technavio - Yahoo FinanceApril 27, 2022 | law360.comTeligent Gets Ch. 11 Disclosure, Voting Plans OK'd In Del. - Law360April 26, 2022 | law360.comUS Trustee Calls Teligent Ch. 11 Plan Releases 'Baffling' - Law360March 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 12, 2022 | law360.comTeligent OK'd For Fast-Tracked Del. Ch. 11 Disclosure Hearing - Law360April 1, 2022 | wsj.comAlex Mandl, Who Gave Up a Top AT&T Job to Lead a Startup, Has Died at Age 78 - The Wall Street JournalFebruary 28, 2022 | bizjournals.comTeligent seeks to convert bankruptcy to Chapter 7 amid impasse with creditors - Philadelphia Business Journal - Philadelphia Business JournalFebruary 25, 2022 | law360.comTeligent Says Stalled Plan Talks Make Liquidation Best Option - Law360February 9, 2022 | news.yahoo.comRobber to be resentenced because judge forgot to ask a question - Yahoo NewsFebruary 8, 2022 | law360.comTeligent Lender Slams Creditor Group Bid To Claw Back Cash - Law360February 3, 2022 | prnewswire.comPAI further bolsters its portfolio with the acquisition of Teligent Sterile Injectable and Topical products - PRNewswireFebruary 3, 2022 | morningstar.co.ukHikma completes acquisition of Teligent's Canadian... - MorningstarJanuary 19, 2022 | law360.comTeligent's 3 Ch. 11 Asset Sales Bring $87M Into Estate - Law360January 18, 2022 | law360.comTeligent's Three Ch. 11 Asset Sales Bring $87M Into Estate - Law360January 17, 2022 | marketwatch.comHikma to Buy Canadian Assets of Teligent for $45.75 Mln - MarketWatchJanuary 17, 2022 | lse.co.ukTOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million | Financial News - London South EastJanuary 17, 2022 | prnewswire.comHikma expands into Canada with acquisition of Teligent sterile injectable assets - PRNewswireDecember 14, 2021 | law360.com3-Part Ch.11 Stalking Horse Sale OK'd For Teligent - Law360December 8, 2021 | nasdaq.comFDA Approves Daré Bioscience's Xaciato For Bacterial Vaginosis - NasdaqDecember 8, 2021 | finance.yahoo.comRocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer - Yahoo FinanceDecember 2, 2021 | marketwatch.comAtropine Sulfate Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2028November 11, 2021 | wsj.comPlaintiffs Want Teligent Price-Fixing Lawsuit to Continue Despite Bankruptcy - The Wall Street JournalSee More Headlines Receive TLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teligent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TLGT CUSIPN/A CIK352998 Webwww.teligent.com Phone(856) 697-1441Fax856-697-1442Employees2,357Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesTimothy B. SawyerPresident, Chief Executive Officer & DirectorAntonio di NicolaVice President-Operations & General ManagerAlyssa LozynskiChief Financial OfficerDevendra ShahVice President-Research & DevelopmentPhilip K. YachmetzSecretary, Chief Legal Officer & Executive VPKey CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors TLGT Stock Analysis - Frequently Asked Questions How were Teligent's earnings last quarter? Teligent, Inc. (NASDAQ:TLGT) released its earnings results on Monday, August, 16th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company earned $10.43 million during the quarter. When did Teligent's stock split? Teligent shares reverse split on the morning of Thursday, May 28th 2020. The 1-10 reverse split was announced on Wednesday, May 27th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tim Sawyer's approval rating as Teligent's CEO? 2 employees have rated Teligent Chief Executive Officer Tim Sawyer on Glassdoor.com. Tim Sawyer has an approval rating of 100% among the company's employees. This puts Tim Sawyer in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Teligent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX), ChemoCentryx (CCXI), Voyager Therapeutics (VYGR), AbbVie (ABBV), General Electric (GE), Biocept (BIOC), Lannett (LCI), Pfizer (PFE), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). This page (NASDAQ:TLGT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teligent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.